Durata Therapeutics to Announce Full Year 2012 Financial Results on Friday, March 8, 2013

Durata Therapeutics to Announce Full Year 2012 Financial Results on Friday,
March 8, 2013

Conference Call to Be Held at 8:30 a.m. Eastern Time

CHICAGO, March 5, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX)
has scheduled its quarterly conference call for Friday, March 8, 2013 at 8:30
a.m. Eastern Time to discuss full year 2012 financial results.

The conference call will be available via phone and webcast. To access the
call, please dial 866-632-4021 for participants in the U.S. or Canada and
404-991-3968 for international callers (reference Conference ID 19456362). A
replay of the call may be accessed through March 22, 2013 by dialing
800-585-8367 for callers in the U.S. and Canada and 404-537-3406 for
international callers (reference Conference ID 19456362). The conference call
will also be webcast live at
http://event.on24.com/r.htm?e=593360&s=1&k=1C554807277DBF38FF83F9CE292BA7AE.

The webcast will as well be available on the Investor Relations section of the
Company's website at www.duratatherapeutics.com.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has now completed two global Phase 3 clinical
trials with its lead product candidate, dalbavancin, for the treatment of
patients with acute bacterial skin and skin structure infections, or ABSSSI.

The Durata Therapeutics, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16463

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans
and prospects constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, as amended. Actual results
may differ materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will cause its
views to change. However, while Durata may elect to update these
forward-looking statements at some point in the future, Durata specifically
disclaims any obligation to do so.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey - Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312)219-7017 - awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.